Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 83Urinary Bladder Neoplasms 31Carcinoma, Renal Cell 9Carcinoma, Transitional Cell 8Kidney Neoplasms 7Recurrence 5Prostatic Hyperplasia 5Neoplasms 5Disease 5Testicular Neoplasms 3Pain, Postoperative 3Pain 3Non-Muscle Invasive Bladder Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Anxiety Disorders 3Sleep Initiation and Maintenance Disorders 2Penile Neoplasms 2Pancreatic Neoplasms 2Motor Activity 2Melanoma 2Lymphoma 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Adenocarcinoma 2Acute Kidney Injury 2Wilms Tumor 1Vulvar Neoplasms 1Vomiting 1Uterine Cervical Neoplasms 1

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Gonadal Disorders × Genitourinary × Clear all
NCT03403777 2019-03-05

Avelumab in Refractory Testicular Germ Cell Cancer.

National Cancer Institute, Slovakia

Phase 2 Completed
8 enrolled
Genitourinary

Gonadal Disorders, Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Diseases, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡